<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: product line launch new products", fill: "#c9a0dc"},
{source: "4: product line launch new products", target: "4: approved by", fill: "#c9a0dc"},
{source: "4: approved by", target: "4: regulatory", fill: "#c9a0dc"},
{source: "4: product line launch new products", target: "5: Additional ", fill: "#4cbb17"},
{source: "5: Additional ", target: "5: clinical data", fill: "#4cbb17"},
{source: "5: clinical data", target: "5: new products", fill: "#4cbb17"},
{source: "5: new products", target: "5: treat coronary artery disease will likely", fill: "#4cbb17"},
{source: "5: treat coronary artery disease will likely", target: "5: necessary", fill: "#4cbb17"},
{source: "5: necessary", target: "5: grow revenue within", fill: "#4cbb17"},
{source: "5: grow revenue within", target: "5: coronary market", fill: "#4cbb17"},
{source: "5: Additional ", target: "9: development", fill: "#ff6347"},
{source: "9: development", target: "9: trial activities", fill: "#ff6347"},
{source: "9: trial activities", target: "9: activities", fill: "#ff6347"},
{source: "9: activities", target: "9: regulatory", fill: "#ff6347"},
{source: "9: regulatory", target: "9: future selling general", fill: "#ff6347"},
{source: "9: future selling general", target: "9: administrative", fill: "#ff6347"},
{source: "9: administrative", target: "9: costs associated with launching", fill: "#ff6347"},
{source: "9: costs associated with launching", target: "9: additional", fill: "#ff6347"},
{source: "9: additional", target: "9: indications", fill: "#ff6347"},
{source: "9: indications", target: "9: significant expenses", fill: "#ff6347"},
{source: "9: significant expenses", target: "9: foreseeable future", fill: "#ff6347"},
{source: "9: development", target: "11: demonstrated profitability over", fill: "#a52a2a"},
{source: "11: demonstrated profitability over", target: "11: profitability", fill: "#a52a2a"},
{source: "11: profitability", target: "11: focused on", fill: "#a52a2a"},
{source: "11: focused on", target: "11: profitability no assurance", fill: "#a52a2a"},
{source: "11: demonstrated profitability over", target: "15: International ", fill: "#00308f"},
{source: "15: International ", target: "15: regulatory approval processes may", fill: "#00308f"},
{source: "15: regulatory approval processes may", target: "15: approval process", fill: "#00308f"},
{source: "15: approval process", target: "15: longer than", fill: "#00308f"},
{source: "15: International ", target: "20: All of Spectranetics ", fill: "#ff6961"},
{source: "20: All of Spectranetics ", target: "20: potential products", fill: "#ff6961"},
{source: "20: potential products", target: "20: approval from", fill: "#ff6961"},
{source: "20: approval from", target: "20: regulatory agencies prior", fill: "#ff6961"},
{source: "20: regulatory agencies prior", target: "20: commercial sale", fill: "#ff6961"},
{source: "20: All of Spectranetics ", target: "22: Companies ", fill: "#4f7942"},
{source: "22: Companies ", target: "22: Contents ", fill: "#4f7942"},
{source: "22: Contents ", target: "22: significant setbacks", fill: "#4f7942"},
{source: "22: significant setbacks", target: "22: various stages", fill: "#4f7942"},
{source: "22: various stages", target: "22: clinical trials even", fill: "#4f7942"},
{source: "22: clinical trials even", target: "22: clinical trials", fill: "#4f7942"},
{source: "22: clinical trials", target: "22: apparently promising", fill: "#4f7942"},
{source: "22: apparently promising", target: "22: earlier trials", fill: "#4f7942"},
{source: "22: Companies ", target: "24: years depending on", fill: "#c41e3a"},
{source: "24: years depending on", target: "24: complexity novelty", fill: "#c41e3a"},
{source: "24: complexity novelty", target: "24: intended use", fill: "#c41e3a"},
{source: "24: years depending on", target: "25: competitors", fill: "#fffdd0"},
{source: "25: competitors", target: "25: offer larger financial incentives", fill: "#fffdd0"},
{source: "25: offer larger financial incentives", target: "25: clinical trials", fill: "#fffdd0"},
{source: "25: competitors", target: "37: technology", fill: "#123524"},
{source: "37: technology", target: "37: generally used adjunctively with", fill: "#123524"},
{source: "37: generally used adjunctively with", target: "37: established therapies", fill: "#123524"},
{source: "37: established therapies", target: "37: such as balloon angioplasty", fill: "#123524"},
{source: "37: such as balloon angioplasty", target: "37: stent implantation", fill: "#123524"},
{source: "37: stent implantation", target: "37: restoring circulation", fill: "#123524"},
{source: "37: restoring circulation", target: "37: obstructed arteries", fill: "#123524"},
{source: "37: technology", target: "40: primary competitors", fill: "#b768a2"},
{source: "40: primary competitors", target: "40: manufacturers", fill: "#b768a2"},
{source: "40: manufacturers", target: "40: products used", fill: "#b768a2"},
{source: "40: products used", target: "40: competing therapies within", fill: "#b768a2"},
{source: "40: competing therapies within", target: "40: atherectomy markets such as", fill: "#b768a2"},
{source: "40: atherectomy markets such as", target: "40: bypass surgery coronary", fill: "#b768a2"},
{source: "40: bypass surgery coronary", target: "40: atherectomy", fill: "#b768a2"},
{source: "40: atherectomy", target: "40: thrombectomy using mechanical methods", fill: "#b768a2"},
{source: "40: thrombectomy using mechanical methods", target: "40: arterial blockages coronary", fill: "#b768a2"},
{source: "40: arterial blockages coronary", target: "40: amputation peripheral", fill: "#b768a2"},
{source: "40: amputation peripheral", target: "40: balloon angioplasty peripheral", fill: "#b768a2"},
{source: "40: primary competitors", target: "54: healthcare providers from using", fill: "#b8860b"},
{source: "54: healthcare providers from using", target: "54: devices which", fill: "#b8860b"},
{source: "54: devices which", target: "54: would adversely affect both", fill: "#b8860b"},
{source: "54: would adversely affect both", target: "54: revenues from", fill: "#b8860b"},
{source: "54: revenues from", target: "54: significantly", fill: "#b8860b"},
{source: "54: significantly", target: "54: revenue from", fill: "#b8860b"},
{source: "54: revenue from", target: "54: disposable products", fill: "#b8860b"},
{source: "54: healthcare providers from using", target: "73: products could", fill: "#a8516e"},
{source: "73: products could", target: "73: obsolete as", fill: "#a8516e"},
{source: "73: obsolete as", target: "73: future innovations", fill: "#a8516e"},
{source: "73: future innovations", target: "73: vascular disease", fill: "#a8516e"},
{source: "73: products could", target: "110: Peter Rentrop ", fill: "#800080"},
{source: "110: Peter Rentrop ", target: "110: certain catheter with", fill: "#800080"},
{source: "110: certain catheter with", target: "110: millimeters", fill: "#800080"},
{source: "110: millimeters", target: "110: currently involved", fill: "#800080"},
{source: "110: currently involved", target: "110: litigation", fill: "#800080"},
{source: "110: Peter Rentrop ", target: "119: following factors may", fill: "#483c32"},
{source: "119: following factors may", target: "119: significantly affect", fill: "#483c32"},
{source: "119: significantly affect", target: "119: fluctuations", fill: "#483c32"},
{source: "119: fluctuations", target: "119: announcements", fill: "#483c32"},
{source: "119: announcements", target: "119: technological innovations", fill: "#483c32"},
{source: "119: technological innovations", target: "119: new products by", fill: "#483c32"},
{source: "119: new products by", target: "119: Spectranetics ", fill: "#483c32"},
{source: "119: Spectranetics ", target: "119: competitors", fill: "#483c32"},
{source: "119: competitors", target: "119: governmental", fill: "#483c32"},
{source: "119: governmental", target: "119: developments", fill: "#483c32"},
{source: "119: developments", target: "119: proprietary", fill: "#483c32"},
{source: "119: proprietary", target: "119: initiation", fill: "#483c32"},
{source: "119: initiation", target: "119: management", fill: "#483c32"},
{source: "119: management", target: "119: litigation", fill: "#483c32"},
{source: "119: litigation", target: "119: conditions", fill: "#483c32"},
{source: "119: conditions", target: "119: operations", fill: "#483c32"},
{source: "119: operations", target: "119: additional", fill: "#483c32"},
{source: "119: additional", target: "119: stockholders", fill: "#483c32"},
{source: "119: following factors may", target: "START_HERE", fill: "#483c32"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Approved_drug">Approved drug</a></td>
      <td>An approved drug is a medicinal preparation that has been validated for a therapeutic use by a ruling authority of a government. This process is usually specific by country, unless specified otherwise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Peripheral_artery_disease">Peripheral artery disease</a></td>
      <td>Peripheral artery disease (PAD) is an abnormal narrowing of arteries other than those that supply the heart or brain. When narrowing occurs in the heart, it is called coronary artery disease, and in the brain, it is called cerebrovascular disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Production_part_approval_process">Production part approval process</a></td>
      <td>Production Part Approval Process (PPAP) is used in the automotive supply chain for establishing confidence in suppliers and their production processes. Actual measurements are taken from the parts produced and are used to complete the various test sheets of PPAP."All customer engineering design record and specification requirements are properly understood by the supplier and that the process has the potential to produce product consistently meeting these requirements during an actual production run at the quoted production rate." Version 4, 1 March 2006Although individual manufacturers have their own particular requirements, the Automotive Industry Action Group (AIAG) has developed a common PPAP standard as part of the Advanced Product Quality Planning (APQP) – and encourages the use of common terminology and standard forms to document project status.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Philips">Philips</a></td>
      <td>Koninklijke Philips N.V. (in Dutch literally "Royal Philips"), commonly shortened to Philips, is a Dutch multinational conglomerate corporation that was founded in Eindhoven in 1891. Since 1997, it has been mostly headquartered in Amsterdam, though the Benelux headquarters is still in Eindhoven.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_patent_law">United States patent law</a></td>
      <td>Under United States law, a patent is a right granted to the inventor of a (1) process, machine, article of manufacture, or composition of matter, (2) that is new, useful, and non-obvious. A patent is the right to exclude others, for a limited time (usually, 20 years) from profiting of a patented technology without the consent of the patent-holder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Angioplasty">Angioplasty</a></td>
      <td>Angioplasty, is also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive endovascular procedure used to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Restenosis">Restenosis</a></td>
      <td>Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Catheter">Catheter</a></td>
      <td>In medicine, a catheter (/ˈkæθətər/) is a thin tube made from medical grade materials serving a broad range of functions. Catheters are medical devices that can be inserted in the body to treat diseases or perform a surgical procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vascular_surgery">Vascular surgery</a></td>
      <td>Vascular surgery is a surgical subspecialty in which diseases of the vascular system, or arteries, veins and lymphatic circulation, are managed by medical therapy, minimally-invasive catheter procedures and surgical reconstruction. The specialty evolved from general and cardiac surgery and includes treatment of the body's other major and essential veins and arteries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Revenue_recognition">Revenue recognition</a></td>
      <td>The revenue recognition principle is a cornerstone of accrual accounting together with the matching principle. They both determine the accounting period in which revenues and expenses are recognized.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Swiss_companies_by_revenue">List of Swiss companies by revenue</a></td>
      <td>Switzerland has a large economy and highly skilled labor force. Fifteen Swiss companies are included on Fortune's "Global 500" list (in 2011).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Berhampur_Municipal_Corporation">Berhampur Municipal Corporation</a></td>
      <td>Berhampur Municipal Corporation(BeMC) is the civic body governing Indian city of Berhampur. Municipal Corporation mechanism in India was introduced during British Rule with formation of municipal corporation in Madras (Chennai) in 1688, later followed by municipal corporations in Bombay (Mumbai) and Calcutta (Kolkata) by 1762.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent">Patent</a></td>
      <td>A patient is any recipient of health care services that are performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, optometrist, dentist, veterinarian, or other health care provider.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lawsuit">Lawsuit</a></td>
      <td>A lawsuit is a proceeding by a party or parties against another in the civil court of law. The archaic term "suit in law" is found in only a small number of laws still in effect today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Multidistrict_litigation">Multidistrict litigation</a></td>
      <td>In United States law, multidistrict litigation (MDL) refers to a special federal legal procedure designed to speed the process of handling complex cases, such as air disaster litigation or complex product liability suits.\n\n\n== Description ==\nMDL cases occur when "civil actions involving one or more common questions of fact are pending in different districts." In order to efficiently process cases that could involve hundreds (or thousands) of plaintiffs in dozens of different federal courts that all share common issues, the Judicial Panel on Multidistrict Litigation (JPML) decides whether cases should be consolidated under MDL, and if so, where the cases should be transferred.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Settlement_(litigation)">Settlement (litigation)</a></td>
      <td>In law, a settlement is a resolution between disputing parties about a legal case, reached either before or after court action begins. A collective settlement is a settlement of multiple similar legal cases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_interest_litigation_in_India">Public interest litigation in India</a></td>
      <td>The chief instrument through which judicial activism has flourished in India is Public Interest Litigation (PIL) or Social Action Litigation (SAL).  Public interest litigation (PIL) refers to litigation undertaken to secure public interest and demonstrates the availability of justice to socially-disadvantaged parties and was introduced by Justice P. N. Bhagwati.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_interest_law">Public interest law</a></td>
      <td>Public interest law refers to legal practices undertaken to help poor, marginalized, or under-represented people, or to effect change in social policies in the public interest, on 'not for profit' terms (pro bono publico), often in the fields of civil rights, civil liberties, religious liberty, human rights, women's rights, consumer rights, environmental protection, and so on.In a celebrated 1905 speech, Louis Brandeis decried the legal profession, complaining that "able lawyers have to a large extent allowed themselves to become adjuncts of great corporations and have neglected their obligation to use their powers for the protection of the people."In the tradition thus exemplified, a common ethic for public-interest lawyers in a growing number of countries remains "fighting for the little guy".\n\n\n== By jurisdiction ==\n\n\n=== Central and Eastern Europe ===\nAt the end of the communist period in the early 1990s, the national legal systems of Central and Eastern Europe were still in a formative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Review_of_Litigation">The Review of Litigation</a></td>
      <td>The Review of Litigation (TROL) is a law journal established in 1980 at the University of Texas School of Law to serve as "a national forum of interchange of academic and practical discussion of various aspects of litigation." The journal publishes articles on "topics related to procedure, evidence, trial and appellate advocacy, alternative dispute resolution, and often-litigated substantive law."The journal publishes four issues annually, one of which is a symposium issue published in collaboration with the litigation section of American Association of Law Schools. Past topics have included mass torts and conflicts of interest.The journal is often cited in published court opinions, and is the most cited law journal in the category "Civil Litigation and Dispute Resolution" in the Washington &amp; Lee Law School law journal rankings as of 2020.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholders'_agreement">Shareholders' agreement</a></td>
      <td>A shareholders' agreement (sometimes referred to in the U.S. as a stockholders' agreement) (SHA) is an agreement amongst the shareholders or members of a company. In practical effect, it is analogous to a partnership agreement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Annual_general_meeting">Annual general meeting</a></td>
      <td>An annual general meeting (AGM, also known as the annual meeting) is a meeting of the general membership of an organization.\nThese organizations include membership associations and companies with shareholders.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SPECTRANETICS CORP      ITEM 1A Risk Factors             Increases in our <font color="blue">Stock Price </font>are <font color="blue">Largely Dependent </font>on our Ability to     <font color="blue">Grow Revenues</font></td>
    </tr>
    <tr>
      <td>Revenue <font color="blue">growth from current levels depends largely on</font> our     ability to <font color="blue">successfully penetrate</font> the <font color="blue">peripheral <font color="blue">atherectomy</font> market with</font> our     CliRpath <font color="blue">product line</font> that was introduced in 2004 and that is <font color="blue">targeted at</font>     total occlusions (blockages) in the legs</td>
    </tr>
    <tr>
      <td>The success of this <font color="blue">launch will</font>     require increased re-order rates from existing customers and <font color="blue">adoption by new</font>     customers</td>
    </tr>
    <tr>
      <td>Beyond the initial CliRpath <font color="blue">product line</font> launch, <font color="blue">new products</font>     will need to be developed and <font color="blue">approved by</font> the FDA and foreign <font color="blue">regulatory</font>     agencies to sustain revenue growth within the peripheral market</td>
    </tr>
    <tr>
      <td><font color="blue">Additional     </font><font color="blue">clinical data</font> and <font color="blue">new products</font> to <font color="blue">treat <font color="blue">coronary artery disease</font> will likely</font>     be <font color="blue">necessary</font> to <font color="blue">grow revenue within</font> the <font color="blue">coronary market</font></td>
    </tr>
    <tr>
      <td>We incurred losses from <font color="blue">operations</font> since our inception in     June 1984 until the <font color="blue">second quarter</font> of 2001, and we <font color="blue">incurred net losses</font> in     the  first  and  <font color="blue">second quarter</font>s of 2002</td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font></font>31, 2005, we had     accumulated dlra72dtta4 million in <font color="blue">net losses since inception</font></td>
    </tr>
    <tr>
      <td>We expect that our     research,  <font color="blue">development</font>  and  clinical  <font color="blue">trial <font color="blue">activities</font></font> and <font color="blue">regulatory</font>     approvals,  together  with  future selling, general and <font color="blue">administrative</font>     <font color="blue">activities</font>  and  the  <font color="blue">costs associated with launching</font> our products for     <font color="blue">additional</font>  <font color="blue">indications</font>,  will  result in <font color="blue">significant expenses</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, we expect the adoption of <font color="blue">Statement </font>123R     <font color="blue">effective</font> January 1, 2006 will result in <font color="blue">significant compensation expense</font> in     <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>Although we <font color="blue">demonstrated <font color="blue">profitability</font> over</font> the last four     years and are <font color="blue">focused on</font> maintaining <font color="blue">profitability</font>, no assurance can be     given that we will be able to maintain <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>The industry in which we compete is subject to     extensive <font color="blue">regulation by</font> the FDA and comparable state and foreign agencies</td>
    </tr>
    <tr>
      <td><font color="blue">Complying </font>with these <font color="blue">regulations</font> is costly and time consuming</td>
    </tr>
    <tr>
      <td><font color="blue">International     </font><font color="blue">regulatory</font> <font color="blue">approval process</font>es may take <font color="blue">longer than</font> the FDA <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>If we fail to comply with applicable <font color="blue">regulatory</font> <font color="blue">requirement</font>s, we may be     subject to fines, suspensions or <font color="blue">revocations</font> of approvals, seizures or     recalls of products, operating restrictions, criminal prosecutions and other     penalties</td>
    </tr>
    <tr>
      <td>We may be unable to obtain future <font color="blue">regulatory</font> approval in a timely     manner, or at all, <font color="blue">especially</font> if existing <font color="blue">regulations</font> are changed or new     <font color="blue">regulations</font> are adopted</td>
    </tr>
    <tr>
      <td>For example, the FDA <font color="blue">approval process</font> for the use     of <font color="blue"><font color="blue">excimer laser</font> <font color="blue">technology</font></font> in <font color="blue">clearing blocked arteries</font> in the leg took     <font color="blue">longer than</font> we anticipated due to requests for <font color="blue">additional</font> <font color="blue">clinical data</font> and     changes in <font color="blue">regulatory</font> <font color="blue">requirement</font>s</td>
    </tr>
    <tr>
      <td>All of <font color="blue">Spectranetics</font>’ <font color="blue">potential products</font> are subject to extensive regulation     and will require <font color="blue">approval from</font> the FDA and other <font color="blue">regulatory</font> agencies prior     to <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>The results from pre-clinical testing and <font color="blue">early clinical</font>     <font color="blue">trials may</font> not be predictive of results obtained in <font color="blue">later <font color="blue">clinical trials</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>in the medical device industry have suffered                                         16       _________________________________________________________________    [56]Table of <font color="blue">Contents       </font><font color="blue">significant setbacks</font> in <font color="blue">various stages</font> of <font color="blue">clinical trials</font>, even in advanced     <font color="blue">clinical trials</font>, after <font color="blue">apparently promising</font> results had been obtained in     <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of safe and <font color="blue">effective</font> products is uncertain and     subject to <font color="blue">numerous risks</font></td>
    </tr>
    <tr>
      <td>The product <font color="blue">development</font> process may take several     years, depending on the type, <font color="blue">complexity</font>, novelty and <font color="blue">intended use</font> of the     product</td>
    </tr>
    <tr>
      <td>Larger <font color="blue">competitors</font> are able to <font color="blue">offer larger financial incentives</font> to     their customers to support their <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Enrollment </font>in our clinical     <font color="blue">trials may</font> be <font color="blue">adversely</font> affected by <font color="blue">clinical trials</font> financed by our larger     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Product  </font><font color="blue">candidates</font>  that  may appear to be promising in     <font color="blue">development</font> may not reach the market for a number of reasons</td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> may:         •  be found in<font color="blue">effective</font>;         •  take longer to progress through <font color="blue">clinical trials</font> than had been     anticipated; or         •  require <font color="blue">additional</font> <font color="blue">clinical data</font> and testing</td>
    </tr>
    <tr>
      <td>Our Small Sales and Marketing Team May Be Unable To Compete With Our     Larger  Competitors  or  <font color="blue">To Reach Potential Customers</font></td>
    </tr>
    <tr>
      <td>Although we are     expanding our sales and <font color="blue">marketing organizations</font>, many of our <font color="blue">competitors</font>     have <font color="blue"><font color="blue">substantially</font> larger sales</font> and <font color="blue">marketing <font color="blue">operations</font> than</font> we do</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>allows those <font color="blue">competitors</font> to spend more time <font color="blue">with potential customers</font> and to     focus  on  a  larger number of potential customers, which gives them a     <font color="blue">significant advantage over</font> our team in making sales</td>
    </tr>
    <tr>
      <td>Additionally, our field     sales organization consists primarily of <font color="blue">individuals with</font> extensive clinical     experience  within hospital catheterization labs; however, their sales     experience is limited</td>
    </tr>
    <tr>
      <td>We are <font color="blue">providing <font color="blue">sales training</font></font> and, as we add new     field sales employees, will attempt to recruit <font color="blue">candidates</font> with more sales     experience</td>
    </tr>
    <tr>
      <td>However, there are <font color="blue">no assurances</font> that our <font color="blue">sales training</font> and     <font color="blue">recruiting will improve productivity within</font> our <font color="blue">field sales organization</font></td>
    </tr>
    <tr>
      <td>Further, there may be more <font color="blue">turnover within</font> the <font color="blue">field sales organization</font>     relative to <font color="blue">past history as</font> a result of our <font color="blue">transition towards</font> a higher     level of <font color="blue">sales skills</font></td>
    </tr>
    <tr>
      <td>Excimer laser     <font color="blue">technology</font> is <font color="blue">generally used adjunctively with</font> more <font color="blue">established therapies</font>     <font color="blue">such as <font color="blue">balloon <font color="blue">angioplasty</font></font></font> and <font color="blue">stent implantation</font> for <font color="blue">restoring circulation</font>     to clogged or <font color="blue">obstructed arteries</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of the <font color="blue">excimer laser</font>     <font color="blue">system depends on</font> our ability to <font color="blue">provide incremental clinical</font> and economic     data that shows the <font color="blue">clinical efficacy</font> and cost <font color="blue">effective</font>ness of, and patient     benefits from, <font color="blue">excimer laser</font> <font color="blue">atherectomy</font> used with <font color="blue">balloon <font color="blue">angioplasty</font></font> and     <font color="blue">stent implantation</font></td>
    </tr>
    <tr>
      <td>Our primary <font color="blue">competitors</font> are <font color="blue"><font color="blue">manufacture</font>rs</font> of     <font color="blue">products used</font> in <font color="blue">competing therapies within</font> the coronary and peripheral     <font color="blue">atherectomy</font> markets, such as:         •  bypass surgery (coronary and peripheral);         •  <font color="blue">atherectomy</font> and <font color="blue">thrombectomy</font>, using mechanical methods to remove     arterial blockages (coronary and peripheral);         •  amputation (peripheral); and         •  <font color="blue">balloon <font color="blue">angioplasty</font></font> (peripheral)</td>
    </tr>
    <tr>
      <td>We also compete with companies marketing lead extraction devices or     removal methods, such as mechanical sheaths</td>
    </tr>
    <tr>
      <td>In the lead removal market, we     compete worldwide with lead removal devices <font color="blue"><font color="blue">manufacture</font>d</font> by Cook Vascular     Inc</td>
    </tr>
    <tr>
      <td>and we compete in Europe with devices <font color="blue"><font color="blue">manufacture</font>d</font> by VascoMed</td>
    </tr>
    <tr>
      <td>Although <font color="blue">balloon <font color="blue">angioplasty</font></font> and stents are <font color="blue">used extensively</font> in the     <font color="blue">coronary vascular system</font>, we do not <font color="blue">compete directly with</font> these products</td>
    </tr>
    <tr>
      <td>Rather, our laser <font color="blue">technology</font> is used as an <font color="blue">adjunctive treatment</font> to balloon     <font color="blue">angioplasty</font> and stents in <font color="blue">complex procedures</font></td>
    </tr>
    <tr>
      <td>Almost all of our <font color="blue">competitors</font> have <font color="blue"><font color="blue">substantially</font> greater financial</font>,     <font color="blue">manufacturing</font>,  marketing  and  <font color="blue">technical resources than</font> we do</td>
    </tr>
    <tr>
      <td><font color="blue">Larger     </font><font color="blue">competitors</font>  have  a broader <font color="blue">product line</font>, which enables them to offer     <font color="blue">customers bundled purchase contracts</font> and <font color="blue">quantity discounts</font></td>
    </tr>
    <tr>
      <td>We expect     <font color="blue">competition</font> to intensify</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [57]Table of <font color="blue">Contents       </font>      We believe that <font color="blue">primary <font color="blue">competitive</font> factors</font> in the <font color="blue">interventional</font>     <font color="blue">cardiovascular market</font> include:         •  the ability to treat a variety of <font color="blue">lesions safely</font> and <font color="blue">effective</font>ly as     demonstrated by credible <font color="blue">clinical data</font>;         •  the impact of <font color="blue">managed care practices</font>, related <font color="blue">reimbursement</font> to the     <font color="blue">health care provider</font>, and <font color="blue">procedure costs</font>;         •  ease of use;         •  size and <font color="blue">effective</font>ness of <font color="blue">sales forces</font>; and         •  research and <font color="blue">development</font> capabilities</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of <font color="blue">atherectomy</font> or <font color="blue">thrombectomy</font> devices include Boston     Scientific,  Guidant,  Possis  Medical,  Fox  Hollow  Technologies and     <font color="blue">Intraluminal Therapeutics</font></td>
    </tr>
    <tr>
      <td>There are other potential <font color="blue">competitors</font>, such as     Pathway Medical and Cardiovascular Systems, that are seeking FDA approval to     market their mechanical <font color="blue">atherectomy</font> devices</td>
    </tr>
    <tr>
      <td>The <font color="blue">initial cost</font> of purchasing our CVX 300 laser unit is substantial     and hospitals and other <font color="blue">healthcare providers</font> are not reimbursed for the cost     of acquiring this unit, but instead are reimbursed for individual procedures     performed using the unit</td>
    </tr>
    <tr>
      <td>Many <font color="blue">competing products</font> do not require an up-front     <font color="blue">investment</font> in the form of a capital equipment purchase, lease, or rental</td>
    </tr>
    <tr>
      <td>As     a  result,  the  <font color="blue">initial cost</font> of purchasing our laser unit <font color="blue">may prevent</font>     hospitals and other <font color="blue">healthcare providers</font> from using our devices, which in     turn would <font color="blue">adversely</font> affect both our <font color="blue">revenues from</font> the sale and rental of     laser  units, and more <font color="blue">significantly</font>, our <font color="blue">revenue from</font> the sale of our     <font color="blue">disposable products</font></td>
    </tr>
    <tr>
      <td>Our laser-based procedures require that the healthcare     <font color="blue">provider use one</font> of our CVX 300 laser units</td>
    </tr>
    <tr>
      <td>We sell our CVX-300 laser units     primarily  to  hospitals,  which  then bill third-party payers such as     <font color="blue">government</font>  programs and <font color="blue">private insurance</font> plans, for the services the     <font color="blue">hospitals provide</font> to individual <font color="blue">patients using</font> the CVX-300 laser unit</td>
    </tr>
    <tr>
      <td>As a     result, hospitals and other <font color="blue">healthcare providers</font> are not reimbursed for the     substantial <font color="blue">initial cost</font> of purchasing the laser unit</td>
    </tr>
    <tr>
      <td>By contrast, many     <font color="blue">competing products</font> and procedures, like <font color="blue">balloon <font color="blue">angioplasty</font></font> do not require     the  purchase  or  lease  of  expensive  equipment</td>
    </tr>
    <tr>
      <td>Moreover, in some     <font color="blue">circumstances</font>, the amount reimbursed to a hospital for <font color="blue">procedures involving</font>     our <font color="blue">products may</font> not be adequate to <font color="blue">allow them</font> to recoup their initial     <font color="blue">investment</font> in our laser unit</td>
    </tr>
    <tr>
      <td>Moreover, because our <font color="blue">catheters</font> and other     <font color="blue">disposable products</font> generally can be used only in <font color="blue">conjunction with</font> our laser     unit, any <font color="blue">limitation</font> of the <font color="blue">acquisition</font> of our <font color="blue">laser units by hospitals</font> and     other <font color="blue">healthcare providers</font> will <font color="blue">adversely</font> affect sales of our disposable     products</td>
    </tr>
    <tr>
      <td>The FDA has required that the label for the     CVX-300 laser unit state that adjunctive <font color="blue">balloon <font color="blue">angioplasty</font></font> was performed     together  with laser <font color="blue">atherectomy</font> in most of the <font color="blue">coronary procedures</font> we     submitted to the FDA for pre-market approval</td>
    </tr>
    <tr>
      <td><font color="blue">Adjunctive </font><font color="blue">balloon <font color="blue">angioplasty</font></font>     requires  the  purchase of a <font color="blue">balloon catheter</font> in addition to the laser     catheter</td>
    </tr>
    <tr>
      <td>The <font color="blue">requirement</font> that our procedures be performed <font color="blue">together with</font>     balloon  <font color="blue">angioplasty</font>  increases the <font color="blue">aggregate cost</font> of performing these     procedures</td>
    </tr>
    <tr>
      <td>As a result, third-party payers may attempt to deny or limit     <font color="blue">reimbursement</font>, including if they determine that a device used in a procedure     was <font color="blue">experimental</font>, was used for a non-approved indication, or was not used in     <font color="blue">accordance with established pay protocols</font> regarding cost-<font color="blue">effective</font> treatment     methods</td>
    </tr>
    <tr>
      <td><font color="blue">Hospitals </font>that have experienced <font color="blue">reimbursement</font> problems or expect to     experience <font color="blue">reimbursement</font> problems may not acquire our <font color="blue">excimer laser</font> systems</td>
    </tr>
    <tr>
      <td>We     derive  <font color="blue">substantially</font> all of our <font color="blue">revenue from</font> the sale or lease of the     CVX-300 laser unit, related <font color="blue">disposable devices</font> and service</td>
    </tr>
    <tr>
      <td><font color="blue">Technological     </font>progress or new <font color="blue">development</font>s in our industry could <font color="blue">adversely</font> affect sales of     our products</td>
    </tr>
    <tr>
      <td>Many companies, some of which have <font color="blue">substantially</font> greater     resources  than we do, are engaged in research and <font color="blue">development</font> for the     treatment and prevention of <font color="blue">coronary artery disease</font> and <font color="blue">peripheral vascular</font>     disease</td>
    </tr>
    <tr>
      <td>These include pharmaceutical approaches as well as <font color="blue">development</font> of     new or improved <font color="blue">angioplasty</font>, ather-                                         18       _________________________________________________________________    [58]Table of <font color="blue">Contents       </font>ectomy,  <font color="blue">thrombectomy</font>,  stents or other devices</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products could</font> be     rendered <font color="blue">obsolete as</font> a result of <font color="blue">future innovations</font> in the treatment of     <font color="blue">vascular disease</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">utilize distributors throughout most</font> of Europe</td>
    </tr>
    <tr>
      <td>The sales and <font color="blue">marketing efforts on</font> our <font color="blue">behalf by distributors</font> in <font color="blue">Europe     </font>could fail to attain long-term success</td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>1, 2006, we commenced the     marketing of <font color="blue">products directly</font> to our German <font color="blue">customers through</font> our <font color="blue">European     </font>sales and clinical organization, following the expiration of an <font color="blue">agreement</font>     with our German <font color="blue">distributor on</font> <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>There can be no assurance     that our <font color="blue">direct sales effort</font> in Germany will be successful</td>
    </tr>
    <tr>
      <td>For  the  year  ended <font color="blue">December </font>31, 2005, our <font color="blue">revenue from</font>     international <font color="blue">operations</font> represented 14 percent of <font color="blue">consolidated revenue</font></td>
    </tr>
    <tr>
      <td>Changes in overseas economic <font color="blue">conditions</font>, war, currency exchange rates,     foreign laws regulating the approval and sales of medical devices, foreign     tax laws or tariffs or other trade <font color="blue">regulations</font> could <font color="blue">adversely</font> affect our     ability to market our <font color="blue">products outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The new product     <font color="blue">approval process</font> in <font color="blue">foreign countries</font> is <font color="blue">often complex</font> and lengthy</td>
    </tr>
    <tr>
      <td>For     example, the <font color="blue">reimbursement</font> <font color="blue">approval process</font> in Japan is taking <font color="blue">longer than</font>     anticipated due to the <font color="blue">complexity</font> of this process</td>
    </tr>
    <tr>
      <td>To the extent we expand     our international <font color="blue">operations</font>, we expect our sales and expenses <font color="blue">denominated</font>     in foreign currencies to expand, therefore increasing the risk that we will     be  <font color="blue">adversely</font>  affected by <font color="blue">fluctuations</font> in currency exchange rates</td>
    </tr>
    <tr>
      <td>We     currently do not hedge against foreign currency <font color="blue">fluctuations</font>, which could     result in reduced <font color="blue">consolidated revenue</font>s or increased operating expenses</td>
    </tr>
    <tr>
      <td>We Have Important Sole Source Suppliers and May Be Unable To Replace     Them  if <font color="blue">They Stop Supplying Us</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">purchase certain components</font> of our     CVX-300  laser unit <font color="blue">from several sole source suppliers</font></td>
    </tr>
    <tr>
      <td>We do not have     <font color="blue">guaranteed commitments from</font> these suppliers and order <font color="blue">products through</font>     <font color="blue">purchase orders placed with</font> these <font color="blue">suppliers from</font> time to time</td>
    </tr>
    <tr>
      <td>While we     believe  that  we could obtain <font color="blue">replacement components from alternative</font>     suppliers, we may be unable to do so</td>
    </tr>
    <tr>
      <td><font color="blue">We May Be Unable to Meet Customer Demand Associated </font>with Growth in     Unit  Volumes</td>
    </tr>
    <tr>
      <td>We have experienced increase unit <font color="blue">volume growth</font> and our     ability to fulfill <font color="blue">customer demand</font> is becoming more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Although we     are  making  what we believe are the <font color="blue">necessary</font> <font color="blue">investment</font>s to increase     <font color="blue">manufacturing</font> capacity, these <font color="blue">investment</font>s may not be sufficient to fulfill     <font color="blue">customer demand</font> on a <font color="blue">timely basis</font>             Potential Product Liability Claims and Insufficient Insurance Coverage     May Hurt Our Business and Stock Price</td>
    </tr>
    <tr>
      <td>We are subject to risk of product     <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>We maintain product <font color="blue">liability</font> insurance with coverage and     aggregate  maximum  amounts  of dlra5cmam000cmam000</td>
    </tr>
    <tr>
      <td>The <font color="blue">coverage limits</font> of our     insurance policies may be inadequate, and <font color="blue">insurance coverage with</font> acceptable     <font color="blue">terms could</font> be unavailable in the future</td>
    </tr>
    <tr>
      <td>We hold patents and licenses to use patented <font color="blue">technology</font>, and have     patent   <font color="blue">applications</font>   pending</td>
    </tr>
    <tr>
      <td>Our  patents  cover  the  <font color="blue">connection</font>     (coupler) between our laser <font color="blue">catheters</font> and the laser unit, general features     of the laser system, <font color="blue">system patents</font> that include the use of our laser and     our <font color="blue">catheters</font> together, and <font color="blue">specific design</font> features of our <font color="blue">catheters</font></td>
    </tr>
    <tr>
      <td>Certain of the coupler patents and <font color="blue">system patents</font> expire in 2010, and we are     currently exploring new <font color="blue">technology</font> and design changes that may extend the     <font color="blue">patent protection</font> for the coupler and <font color="blue">system patents</font>, however, there can be     no assurance we will be successful in doing so</td>
    </tr>
    <tr>
      <td>In addition, the patents we own and <font color="blue">license may</font> not     be  <font color="blue">sufficiently</font>  broad  to  protect  our <font color="blue">technology</font> or to give us any     <font color="blue">competitive</font>  advantage</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patents could</font> be <font color="blue">challenged as invalid</font> or     <font color="blue">circumvented</font>  by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In addition, the laws of <font color="blue">certain foreign</font>     countries do not protect our <font color="blue"><font color="blue">intellectual property</font> rights</font> to the <font color="blue">same extent</font>     as do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We could be <font color="blue">adversely</font> affected if any of our <font color="blue">licensors terminate</font>     our licenses to use patented <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Spectranetics</font> </font>respects the <font color="blue"><font color="blue">intellectual property</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>However,  there may be patents and patent <font color="blue">applications</font> owned by others     relating to laser and fiber-optic technologies, which, if determined to be     valid and enforceable, may be <font color="blue">infringed by</font> <font color="blue">Spectranetics</font></td>
    </tr>
    <tr>
      <td>Holders of certain     patents, including holders of patents involving the use of lasers in the     body, <font color="blue">may contact us</font> and request that we <font color="blue">enter into license</font>                                         19       _________________________________________________________________    [59]Table of <font color="blue">Contents       </font><font color="blue">agreement</font>s for the underlying <font color="blue">technology</font> and pay them royalties, which could     be substantial</td>
    </tr>
    <tr>
      <td>For example, we have been made aware of a <font color="blue">patent issued</font> to     Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Peter Rentrop </font>for a <font color="blue">certain catheter with</font> a diameter of less than 0dtta9     <font color="blue">millimeters</font> and are <font color="blue">currently involved</font> in <font color="blue">litigation</font> regarding this patent</td>
    </tr>
    <tr>
      <td>See “Legal Proceedings” herein for further discussion of this <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot guarantee</font> that we <font color="blue">will prevail</font> in this <font color="blue">litigation</font> or that another     <font color="blue">patent holder will</font> not file a <font color="blue">lawsuit against us</font> and prevail</td>
    </tr>
    <tr>
      <td>If we decide     that we need to obtain a license to use any <font color="blue">intellectual property</font>, we may be     unable to obtain these <font color="blue">licenses on</font> favorable terms or at all or we may be     required  to  make  substantial  royalty or other payments to use this     <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>We may not be able to develop or otherwise obtain     alternative <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation   </font><font color="blue">concerning</font>  patents  and  <font color="blue">proprietary</font>  rights  is     time-consuming, expensive, unpredictable and <font color="blue">could divert</font> the efforts of our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse ruling could</font> subject us to significant <font color="blue">liability</font>,     require us to <font color="blue">seek licenses</font> and restrict our ability to <font color="blue">manufacture</font> and sell     our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">Stock Price </font>May Continue To Be Volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our     <font color="blue">common stock</font>, similar to other medical device companies, has been, and is     likely  to  continue to be, <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors may</font>     <font color="blue">significantly</font> affect the <font color="blue">market price</font> of our <font color="blue">common stock</font>:         •  <font color="blue">fluctuations</font> in operating results;         •  <font color="blue">announcements</font> of <font color="blue">technological innovations</font> or <font color="blue">new products</font> by     <font color="blue"><font color="blue">Spectranetics</font> </font>or our <font color="blue">competitors</font>;         •  <font color="blue">government</font>al regulation;         •  <font color="blue">development</font>s with respect to patents or <font color="blue">proprietary</font> rights;          •   public  concern  regarding  the safety of products developed by     <font color="blue"><font color="blue">Spectranetics</font> </font>or others;         •  the <font color="blue">initiation</font> or cessation in coverage of our <font color="blue">common stock</font>, or changes     in ratings of our <font color="blue">common stock</font>, by securities analysts;         •  past or future <font color="blue">management</font> changes;         •  <font color="blue">litigation</font>;         •  general market <font color="blue">conditions</font>; and         •  financing of future <font color="blue">operations</font> through <font color="blue">additional</font> issuances of equity     securities,  which may result in dilution to existing <font color="blue">stockholders</font> and     falling stock prices</td>
    </tr>
    <tr>
      <td>Protections Against Unsolicited Takeovers in Our Rights Plan, Charter     and Bylaws May Reduce or Eliminate Our Stockholders’ Ability To Resell Their     Shares at a <font color="blue">Premium Over Market Price</font></td>
    </tr>
    <tr>
      <td>We have a <font color="blue">stockholders</font>’ rights plan     that <font color="blue">may prevent</font> an unsolicited change of control of <font color="blue">Spectranetics</font></td>
    </tr>
    <tr>
      <td>The     rights plan may <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our <font color="blue">common stock</font> or the     ability of <font color="blue">stockholders</font> to <font color="blue">participate</font> in a <font color="blue">transaction</font> in which they might     otherwise receive a premium for their shares</td>
    </tr>
    <tr>
      <td>In addition, the issuance of     <font color="blue">preferred stock</font> or <font color="blue">common stock</font> upon exercise of <font color="blue">rights issued under</font> this     plan <font color="blue">could dilute</font> the voting, liquidation and other <font color="blue">economic rights</font> or our     other <font color="blue">stockholders</font> and make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire     us</td>
    </tr>
    <tr>
      <td>However, our <font color="blue">stockholder rights</font> plan by its terms will expire in May,     2006 and we do not intend to extend or renew the rights plan</td>
    </tr>
    <tr>
      <td>Our charter and bylaws contain provisions relating to issuance of     <font color="blue">preferred stock</font>, special meetings of <font color="blue">stockholders</font> and <font color="blue">amendments</font> of the     bylaws that could have the effect of delaying, <font color="blue">deferring</font> or preventing an     unsolicited change in the control of <font color="blue">Spectranetics</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Board of Directors     </font>is elected for staggered three-year terms, which prevents <font color="blue">stockholders</font> from     electing all <font color="blue">directors at each annual meeting</font> and may have the effect of     delaying or <font color="blue">deferring</font> a change in control</td>
    </tr>
  </tbody>
</table>